摘要
Philadelphia-positive acute lymphoblastic leukemia （Ph＋ ALL） accounts for approximately 25-33% of all adult ALL cases. Its prognosis was dismal until the introduction of tyrosine kinase inhibitors （TKls） in clinical applications. TKIs combined with chemotherapy resulted in higher rates of complete remission （CR） and complete molecular remission （CMR） compared with chemotherapy alone. However, allogeneic stem cell transplantation （allo-SCT） has been considered the only potentially curative option once the patient achieves CR. There are still questions that remain unanswered regarding the use of TKis prior to or after alIo-SCT. Imatinib was the first TKI used for induction and maintenance therapy in combination with chemotherapy. What is its optimal dosage and how long should it be maintained＇？
Philadelphia-positive acute lymphoblastic leukemia （Ph＋ ALL） accounts for approximately 25-33% of all adult ALL cases. Its prognosis was dismal until the introduction of tyrosine kinase inhibitors （TKls） in clinical applications. TKIs combined with chemotherapy resulted in higher rates of complete remission （CR） and complete molecular remission （CMR） compared with chemotherapy alone. However, allogeneic stem cell transplantation （allo-SCT） has been considered the only potentially curative option once the patient achieves CR. There are still questions that remain unanswered regarding the use of TKis prior to or after alIo-SCT. Imatinib was the first TKI used for induction and maintenance therapy in combination with chemotherapy. What is its optimal dosage and how long should it be maintained＇？
